| Date | Title | Description |
| 22.04.2026 | STORM Therapeutics Secures $56 Million, Advances Novel Sarcoma Therapy to Phase 2 | STORM Therapeutics, a clinical-stage biotechnology firm, secured $56 million in Series C financing. This significant capital infusion will drive the advancement of STC-15, its groundbreaking first-in-class METTL3 inhibitor. STC-15 has now e... |
| 20.04.2026 | STORM Therapeutics secures $56 million series C financing and doses first patient in phase 2 Sarcoma Trial of STC‑15 | The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indications
First‑in‑class METTL3 inhibitor reprograms malignant progenitor cells by modulating mRNA methylation
16 April 2026, Cambridge, UK: STORM Th... |
| 16.04.2026 | STORM Therapeutics Raises $56M in Series C Funding | STORM Therapeutics, a Cambridge, UK-based, clinical stage company targeting RNA modifications to reprogram cells and develop novel cancer therapies, raised $56M in Series C funding.
Backers included M Ventures, Pfizer Ventures, Taiho Ventur... |
| 22.03.2026 | Crossbow Therapeutics Fuels T-Cell Engager Pipeline with $77 Million Series B | Crossbow Therapeutics secured $77 million in Series B funding to propel its innovative TCR-mimetic antibody cancer therapies. This substantial capital injection will accelerate the development of critical T-cell engager programs. Funds will... |
| 19.03.2026 | Crossbow Therapeutics Raises $77M in Series B Funding | Crossbow Therapeutics, a Cambridge, MA-based biotechnology company developing antibody therapies to treat a broad range of cancers, raised $77M in Series B funding.
The round was led by Taiho Ventures and Arkin Bio Capital, with participati... |
| 18.03.2026 | Crossbow Therapeutics: $77 Million Raised To Advance TCR-Mimetic Antibody Cancer Therapies | Crossbow Therapeutics announced it has raised $77 million in a Series B financing to advance the development of its TCR-mimetic antibody therapies designed to treat a broad range of cancers. The funding round was co-led by Taiho Ventures an... |
| 31.01.2026 | TRexBio Secures $50M to Accelerate Treg-Targeted Immunotherapy Pipeline | TRexBio secured $50 million. This clinical-stage biotech develops precision immunoregulatory medicines. Its focus: tissue regulatory T cell (Treg) biology. Funding fuels clinical and preclinical pipeline advancement. Lead program TRB 061, a... |
| 28.01.2026 | TRexBio: $50 Million Raised To Advance Tissue-Targeted Treg Immunology Pipeline | TRex Bio, a clinical-stage biotechnology company focused on precision immunoregulatory medicines derived from tissue regulatory T cell biology, announced it closed an oversubscribed $50 million financing to support clinical and preclinical ... |
| 27.01.2026 | TRexBio Raises $50M in Funding | TRexBio, a San Francisco, CA-based clinical-stage biotechnology company, raised $50M in funding.
Backers included new investors Janus Henderson Investors, Balyasny Asset Management L.P. and Affinity Asset Advisors, as well as existing inves... |
| 12.01.2026 | Vibrant Therapeutics: $61 Million Closed And Han Lee Named As Co-CEO | Vibrant Therapeutics, a clinical-stage biotech developing “logic-gated” therapeutics designed to activate selectively in diseased tissue, announced it has raised $61 million in new financing and appointed Han Lee, Ph.D. as co-chief executiv... |
| 12.01.2026 | Vibrant Therapeutics Raises $61M in Funding | Vibrant Therapeutics, a Guangzhou, China- and Cambridge, MA-based clinical-stage biotechnology company developing new therapeutics, raised $61M in new financing.
The round included new investors Pfizer Ventures and Apricot Capital with part... |
| 11.01.2026 | Enodia Therapeutics Secures €20.7M Seed Funding to Pioneer Protein Degradation with AI | Enodia Therapeutics, a pioneering biotech firm, secured a significant €20.7 million ($25 million) seed funding round. This vital capital propels its innovative small-molecule platform, a breakthrough approach targeting protein degradation a... |
| 11.01.2026 | Enodia Therapeutics Raises €20.7M to Target "Undruggable" Proteins with SEC61 Platform | Enodia Therapeutics, a Paris-based biotech, has secured €20.7 million ($25 million) in seed funding. Argobio Studio launched the company. Enodia develops small molecules. Its platform targets protein degradation at the point of synthesis. I... |
| 10.01.2026 | Enodia Therapeutics: €20.7 Million Seed Funding Closed To Advance SEC61-Based Small-Molecule Protein Degradation Platform | Enodia Therapeutics has raised €20.7 million (about $25 million) in a seed financing to advance a discovery platform that uses proteomics and machine learning to develop small molecules that degrade disease-driving proteins at the point of ... |
| 09.01.2026 | Argobio Launches Enodia With €20.7 Million Seed Round To Develop Small Molecules For Protein Degradation | Argobio Studio announced it has launched Enodia Therapeutics and completed a €20.7 million ($25 million) seed financing to advance a small-molecule platform for targeted protein degradation at the point of protein synthesis, enabled by prot... |
| 08.01.2026 | Enodia Therapeutics Raises €20.7M in Seed Funding | Enodia Therapeutics, a Paris, France-based biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, raised €20.7m (US$25m) in Seed financing.
The round was co-led by Elaia, ... |
| 24.12.2025 | FoRx Therapeutics: $50 Million Series A Raised To Advance FORX-428 | FoRx Therapeutics, a clinical-stage biotech developing precision oncology medicines, has closed an insider-led $50 million (CHF 40 million) Series A financing to advance its lead candidate, FORX-428, into and through Phase 1 clinical develo... |
| 19.12.2025 | FoRx Therapeutics Secures €42M for Next-Gen PARG Inhibitor Cancer Therapy | FoRx Therapeutics secured €42 million ($50 million) in Series A funding. The Swiss biotech targets advanced cancers. Its lead candidate, FORX-428, is a novel PARG inhibitor. This drug disrupts the DNA Damage Response. It aims to treat tumor... |
| 18.12.2025 | Swiss BioTech FoRx Therapeutics closes €42 million for next-generation DNA repair cancer therapy | Basel-based FoRx Therapeutics, a clinical-stage BioTech company developing precision anti-cancer therapeutics, today announced the close of an insider-led €42 million ($50 million) Series A financing.
Existing investors including EQT Life S... |
| 11.12.2025 | Triana Biomedicines: $120 Million Series B Secured To Advance Molecular Glue Degrader Pipeline | Triana Biomedicines has closed an oversubscribed $120 million Series B financing round that will accelerate development of its molecular glue degrader platform and advance its lead program, TRI-611, toward clinical proof-of-concept in patie... |
| 02.12.2025 | TRIMTECH Therapeutics appoints Alison Lawton as Chair of the Board | Cambridge, UK, 2 December 2025: TRIMTECH Therapeutics, a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced the appointment ... |
| 25.11.2025 | MindImmune: $30 Million Series A Closed As Isaac Stoner Becomes CEO | MindImmune Therapeutics has expanded its Series A financing to $30 million and appointed life sciences entrepreneur Isaac Stoner as its new Chief Executive Officer, marking a significant milestone for the neuroinflammation-focused biotechno... |
| 19.11.2025 | Artios Pharma Secures $115M to Advance Cancer Therapies | Artios Pharma, a UK-based biotech firm, has secured $115 million in Series D funding. The financing aims to boost the development of its precision cancer treatments. Focus on DNA damage response (DDR) is key. Funds will advance clinical tri... |
| 17.11.2025 | Artios raises $115M Series D to accelerate first-in-class cancer therapies | Biotech company Artios today announced the successful close of an oversubscribed $115 million Series D financing.
Artios is pioneering next-generation approaches in the DNA damage response (DDR) field through its comprehensive anti-cancer a... |
| 17.11.2025 | €99 million Series D fuels Artios’ expansion of precision cancer treatment pipeline | Artios Pharma Limited, a British biopharmaceutical company committed to realising the therapeutic potential of targeting the DNA damage response (DDR) in cancer, today announced the successful close of an oversubscribed €99 million ($115 mi... |
| 22.10.2025 | EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion | EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion
Wed, Oct 22, 2025 09:20 CET Report this content
Ipsen and ImCheck Therapeutics have entered into a definitive share purchase agre... |
| 02.10.2025 | Cartography Raises $67M in Series B Funding | Cartograpgy, a San Francisco, CA-based oncology company advancing a pipeline of T-cell engaging bispecific and multi-specific antibody therapeutics that target novel and highly specific tumor antigens, raised $67M in Series B funding.
The r... |
| 05.03.2025 | TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases | Cambridge, UK, 05 March 2025: TRIMTECH Therapeutics, a biotech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases, today announced the closing of its $31 million (£25 million) seed funding ... |
| 13.11.2018 | Kymera Therapeutics Announces $65 Million Series B | Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough medicines for patients, announced today that it has completed a $65 million Series B financing. The financing will support the ... |
